key: cord-0845764-medqmot4
authors: Gozalbo-Rovira, R.; Gimenez, E.; Latorre, V.; Frances-Gomez, C.; Albert, E.; Buesa, J.; Marina, A.; Blasco, M. L.; Signes-Costa, J.; Rodriguez-Diaz, J.; Geller, R.; Navarro, D.
title: SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 Patients
date: 2020-07-24
journal: nan
DOI: 10.1101/2020.07.22.20159673
sha: 8d48f700809c8cbf09d75ef8a80a0d2147218525
doc_id: 845764
cord_uid: medqmot4

Background: The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity. Patients and Methods: This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers were measured in a GFP reporter-based pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts. Results: The overall correlation between levels of both antibody measurements was good (Rho=0.79; P=0<0.001). SARS-CoV-2 RBD IgG and NtAb50 levels in sera collected up to day 30 after the onset of symptoms were comparable between ICU and non-ICU patients (P=>0.1). The percentage of patients who exhibited high NtAb50 titers ([≥]160) was similar (P=0.20) in ICU (79%) and non-ICU (60%) patients. Four ICU patients died; two of these achieved NtAb50 titers [≥]1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0-<0.2) or weak (Rho=>0.2-<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum levels pro-inflammatory biomarkers. Conclusions: The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 severity

7 phosphate-buffered saline-Tween (PBS-T) containing 1% bovine serum albumin and 144 run in triplicate (mean values are reported). The plates were incubated with 1:5,000 145 dilution of horseradish peroxidase (HRP)-conjugated goat anti-human IgG (Jackson 146 Laboratories). After three washes with PBS-T, the binding was detected using 147

SigmaFast OPD reagent (Sigma) according to manufacturer's recommendation. Color 148 development was stopped with 3M H 2 SO 4 and read on a Multiskan FC (ThermoFischer 149 Scientific) plate reader at 492 nm. Serial sera from individual patients were analyzed in 150 the same run. The cut-off discriminating between positive and negative sera was set as 151 the mean absorbance of control sera plus three times the standard deviation. SARS-152

CoV-2 RBD IgG avidity index was calculated as the percentage of measured optical 153 density (OD) in 6M urea-treated wells relative to that in the untreated wells: AI (%) = 154 OD of urea-treated well × 100/OD of non-urea-treated well [26] . A positive-control 155 (high avidity) specimen derived from a convalescent-phase serum from a COVID-19 156 patient (AI, 84%) was included on each ELISA plate. 157

A green fluorescent protein (GFP) reporter-based neutralization assay which used a 159 non-replicative vesicular stomatitis virus pseudotyped with the SARS-CoV-2 spike 160 protein (VSV-S) was optimized as previously described (see supplementary methods) 161 [27] [28] [29] . Neutralization assays were performed on Vero cells. Sera were heat-inactivated 162 for 30 minutes at 56°C then brought to an initial dilution of 1/10, followed by four 4-163 fold dilutions in duplicate. Each dilution was mixed with an equal volume containing 164 1,250 focus forming units of the VSV-S virus and incubated at 37ºC for 1 h. The 165 mixture was then added to Vero cells in 96-well plates and incubated for 18 hours, after 166 which GFP expression was measured using a live cell microscope system (IncuCyteS3, 167 Sartorious). Background fluorescence from uninfected cells was subtracted from all 168 8 values, followed by standardization to the average GFP expression of mock-treated, 169 infected cells. All sera which did not reduce viral replication by 50% at a 1/20 dilution 170 were considered non-neutralizing and were arbitrarily assigned a value of 1/10. All sera 171 that did not result in >70% recovery of GFP signal at the highest antibody dilution were 172 retested using 5-fold dilutions ranging between 100 and 12,500-fold. Finally, the lowest 173 antibody dilution resulting in >50% virus neutralization was used as the NtAb 50 value. 174

Here, we considered high NtAb 50 titers those ≥ 1/160, as this is the minimum NtAb titer 175 of plasma from COVID-19 convalescent individuals recommended by the FDA for 176 therapeutic use [30] . 177

Clinical laboratory investigation included complete blood count and levels of ferritin, 179

Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH) and interleukin-6 180 (IL-6) quantitated in sera that were later used for SARS-CoV-2 RBD IgGs and NtAb 181 testing. 182

Frequency comparisons for categorical variables were carried out using the Fisher exact 184 test. Differences between medians were compared using the Mann-Whitney U-test. 185

Spearman's rank test was used to assess the correlation between continuous variables 186 using the entire dataset (i.e. individuals with single and repeated measurements). 187

Receiver operating characteristic (ROC) curve analysis was performed to identify the 188 optimal SARS-CoV-2 RBD IgG level predicting NtAb titers above a certain threshold. 

Patients hospitalized in the pneumology ward (n=27) and ICU (n=24) were matched for 195 sex and age, the presence of co-morbidities and the time elapsed from the day of onset 196 of symptoms to first serum sample collection (Table 1 ). As expected, ICU patients were 197 hospitalized for longer periods. Median serum levels of several pro-inflammatory 198 biomarkers, such as LDH, dimer-D and IL-6, were significantly higher in ICU patients 199 than in non-ICU patients, further confirming their association with COVID-19 severity 200 [2] [3] [4] [5] . In contrast, the median total lymphocyte counts did not differ across comparison 201 groups (Table 1) . 202

We first aimed to determine whether SARS-CoV-2 RBD IgGs quantified by ELISA 204 could be used as a proxy for NtAb 50 titers, as measured in a reporter-based SARS-CoV-205 2 spike protein pseudotyped VSV neutralization platform. As shown in Figure 1 

SARS-CoV-2 RBD IgGs and NtAb 50 levels at different times after the onset of 212 symptoms are shown in Figure 2 . Overall, serum levels of both antibody tests were seen 213 to increase significantly in parallel over time, although the median peak NtAb 50 titer 214 was reached earlier (between days 11-20) than that of RBD-specific IgGs (between days 215 10 period, while RBD-specific IgGs decreased slightly afterwards. Sequential sera were 217 available from 20 patients, most of whom (n=17) were at ICU. The kinetics profile from 218 both antibody assays was found to vary widely across patients (Figure 3 Measurements from both antibody assays weakly correlated with total lymphocyte 246 counts. As a complementary approach, we grouped sera into two categories (high 247 NtAb 50 titers: ≥ 1/160 and low NtAb 50 titers: <1/160), and assessed whether median 248 levels of the abovementioned parameters differed across groups. We found this not to be 249 the case (Supplementary Figure 2) . 250

Here, in addition to further characterizing the antibody response to SARS-CoV-2 in 252 hospitalized COVID-19 patients, we mainly aimed to determine whether a relationship 253 could be established between the magnitude of SARS-CoV-2 RBD IgG and NtAb levels 254 and the "inflammatory state" of patients, which has been shown to directly correlate 255 with COVID-19 severity and prognosis [2-5]. 256

We found that SARS-CoV-2 RBD IgG levels correlated fairly well with NtAb titers, as 257 quantitated by a VSV reporter virus pseudotyped with SARS-CoV-2 S protein (VSV-S), 258 thus lending support to the assumption that the former parameter is a reasonably reliable 259 proxy for the latter. This was expected as RBD encompasses the most critical region of 260 SARS-CoV-2 for ACE2 receptor binding [8, 9] . Moreover, we could define a SARS-261

CoV-2 RBD IgG threshold (≥ 2.34 AU/ml) predicting NtAb titers IgGs. Detection of NtAb at the early stages of COVID-19, irrespective of disease 277 severity, has been previously reported [18, 35] . By the end of the follow-up period more 278 than two-thirds of patients in either ward had developed NtAb titers >1/160. 279

An interesting observation was that SARS-CoV-2 RBD IgGs avidity was quite low 280 (<10%) in most sera, which were collected up to 2 months following the onset of 281 symptoms, and showed minimal increase over time. This antibody avidity maturation 282 pattern is reminiscent of that observed during SARS [38] . Remarkably, no correlation 283 was found between SARS-CoV-2 RBD IgG AIs and NtAb 50 titers. This finding is in 284 agreement with the idea that limited to no affinity maturation is required from the 285 germline to achieve a potent NtAb response to RBD [39] . 286

The alleged association between high SARS-CoV-2 antibody levels and COVID-19 287 severity reported in a number of studies [17-22] is a matter of concern. If found to be 288 the case, a plausible explanation for this observation may be that patients experiencing 289 13 severe forms of the disease are exposed to higher and more perdurable viral burdens 290 [18] ; this, however, would call into question the role of antibodies in contributing to 291 SARS-CoV-2 clearance. Alternatively, it may simply represent an epiphenomenom in 292 the setting of an overall exaggerated immune response driven by "cytokine storms", or 293 may constitute a relevant pathogenetic mechanism involved in lung tissue damage 294 (antibody-dependent enhancement) [15] . 295

The data presented herein do not support the abovementioned association. In effect, we 296 failed to find differences in SARS-CoV-2 RBD IgGs or SARS-CoV-2 NtAb 50 levels 297 within the first 30 days after the onset of symptoms between ICU and non-ICU patients 298 who were matched for age, sex and co-morbidities. Furthermore, 2 out of the 4 ICU 299 patients who died had relatively low NtAb 50 titers (1/80). Liu and colleagues [19] 300 showed that oxygen requirement in patients was independently associated with NtAb 50 301 levels, as measured by both a pseudotyped reporter virus or live SARS-CoV-2 302 neutralization assay. Nevertheless, this finding should be interpreted with caution 303 provided that only 8 ICU patients were recruited and these were much older than those 304 in the non-ICU group. Wang et al. [18] between NtAb 50 titers and absolute lymphocyte counts was observed. As stated above, 332 the comparison between the two studies is not straightforward. 333

The current study has several limitations. First, its retrospective nature. Second, cohort 334 size is relatively small in our study. Third, IL-6 data was only available from 18 patients 335 (all but one at ICU); in addition, all these patients were treated with tocilizumab. 

Clinical course and risk factors for mortality of adult 379 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of coronavirus disease

Immunopathology 385 of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and 386 Immune-Therapeutic Implications

Immunopathology and Rationale for Potential Treatment and Preventive Strategies in 389 COVID-19

SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not 391 warped minds

Isolation of Potent SARS-CoV-2 Neutralizing 393

Antibodies and Protection From Disease in a Small Animal Model Science

The receptor binding domain of the 396 viral spike protein is an immunodominant and highly specific target of antibodies in 397 SARS-CoV-2 patients

Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of 400

Dissecting antibody-mediated protection against SARS-CoV-2

A SARS-CoV-2 Infection Model in Mice 404

Demonstrates Protection by Neutralizing Antibodies

Mice against SARS-CoV-2 Infection

Treatment of 5 critically ill patients with COVID-19 409 with convalescent plasma

Effectiveness of convalescent plasma therapy in severe 411 COVID-19 patients

Implications of antibody-dependent enhancement of infection for SARS-CoV-2 414 countermeasures

Antibodies to SARS-CoV-2 and their potential for therapeutic 416 passive immunization

Clinical and immunological assessment of 418 asymptomatic SARS-CoV-2 infections

Kinetics of viral load and antibody response in 421 relation to COVID-19 severity

High neutralizing antibody titer in intensive care unit 423 patients with COVID-19

Virological assessment of hospitalized 425 patients with COVID-2019

Severe Acute Respiratory Syndrome 427

Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg 428

Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in 431

Convalescent Plasma. bioRxiv

Neutralizing Antibodies Responses to SARS-CoV-2

COVID-19 Inpatients and Convalescent Patients

SARS-CoV-2-reactive interferon-γ-producing 435

CD8+ T cells in patients hospitalized with coronavirus disease 2019

Structure of the SARS-CoV-2 spike receptor-binding 438 domain bound to the ACE2 receptor

Multicenter evaluation of a rapid and convenient method for determination of 441 cytomegalovirus immunoglobulin G avidity

A vesicular stomatitis virus replicon-based bioassay 443 for the rapid and sensitive determination of multi-species type I interferon

Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus 447 pseudotypes

SARS-CoV-2 Cell Entry 449

Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease 450

30. Recommendations for Investigational COVID-19 Convalescent Plasma

Rapid generation of neutralizing 456 antibody responses in COVID-19 patients

Effect of Convalescent Plasma Therapy on Time to 458

Clinical Improvement in Patients With Severe and Life-threatening

Convalescent plasma therapy for the 461 treatment of patients with COVID-19: Assessment of methods available for antibody 462 detection and their correlation with neutralising antibody levels

Temporal profiles of viral load in posterior 465 oropharyngeal saliva samples and serum antibody responses during infection by SARS-466

CoV-2: an observational cohort study

Neutralizing antibody responses to SARS-CoV-2 in a 468

COVID-19 recovered patient cohort and their implications

Detection of SARS-CoV-2-specific humoral and 471 cellular immunity in COVID-19 convalescent individuals

Potent Neutralizing Monoclonal Antibodies Directed 474 to Multiple Epitopes on the SARS-CoV-2 Spike

Antibody avidity 477 maturation during severe acute respiratory syndrome-associated coronavirus infection

Rational vaccine design in the time of COVID-19

/ml)

The members of the Decoy-SARS-CoV-2 Study Group